Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Depression Therapeutics Market, by Drug Type, Distribution Channel, and Region - Global Trends, and Forecast till 2025

Published by Coherent Market Insights Product code 629603
Published Content info 171 Pages
Delivery time: 2-3 business days
Price
Back to Top
Depression Therapeutics Market, by Drug Type, Distribution Channel, and Region - Global Trends, and Forecast till 2025
Published: February 14, 2018 Content info: 171 Pages
Description

Antidepressants are prescribed in serious to mild mental health conditions such as major depression and anxiety. Antidepressant drug category is highly lucrative due to low availability of alternative drug therapies for treatment of such disorders. Drug manufacturers are increasingly advancing the antidepressant drug category by introducing innovative therapies such as selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs). Depression is one of the most common mental disorders, which are primarily treated by antidepressants. According to National Health Service Digital (NHS Digital), UK, antidepressant medication prescriptions observed the largest increase in 2016.

Market Dynamics

The global depression therapeutics market is driven by factors such as absence of alternative therapies and high presence of generic drug manufacturers in the market. Increasing number of major drugs are losing patent protection due to which increasing number of generic manufacturers are developing product variations, this in turn is boosting the growth of the market. Proven effectiveness of these medications in improving medical outcomes and increasing prevalence of disorders such as depression are fueling growth of the market. However, life threatening side effects associated with these medications as indicated by the black box warning on the packaging, as well as lack of research and development by major players are expected to hinder growth of the depression therapeutics market.

Key features of the study:

This report provides in-depth analysis of the global depression therapeutics market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global depression therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key companies covered as a part of this study include Pfizer, Inc., Eli Lilly and Company, AstraZeneca Plc, Allergan Plc, GlaxoSmithKline Plc, Intellipharmaceutics International, Inc., Takeda Pharmaceutical Company Limited, H.Lundbeck A/S, Otsuka Holdings Co.,Ltd., Apotex, Inc., Shionogi & Co. Ltd., Zhejiang Hua Hai Pharmaceutical Co., Ltd, and Chengdu Kanghong Pharmaceutical Group Co.,Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics

The global depression therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global depression therapeutics market

Detailed Segmentation:

  • Global Depression Therapeutics Market, By Drug Type:
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Selective Norepinephrine Reuptake Inhibitors (SNRIs)
  • Others
  • Global Depression Therapeutics Market, By Distribution Channel:
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Global Depression Therapeutics Market, By Geography:
  • North America
  • By Drug Type
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Selective Norepinephrine Reuptake Inhibitors (SNRIs)
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • U.S.
  • Canada
  • Mexico
  • Europe
  • By Drug Type
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Selective Norepinephrine Reuptake Inhibitors (SNRIs)
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Drug Type
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Selective Norepinephrine Reuptake Inhibitors (SNRIs)
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • China
  • India
  • Japan
  • Southeast Asia
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • South America
  • By Drug Type
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Selective Norepinephrine Reuptake Inhibitors (SNRIs)
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • Brazil
  • Argentina
  • Colombia
  • Rest of South America
  • Middle East & Africa
  • By Drug Type
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Selective Norepinephrine Reuptake Inhibitors (SNRIs)
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • By Country:
  • Saudi Arabia
  • UAE
  • Egypt
  • Nigeria
  • South Africa
  • Rest of Middle East & Africa
  • Company Profiles
  • Pfizer, Inc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Eily Lilly, and Company
  • AstraZeneca Plc
  • Allergan Plc
  • GlaxoSmithKline Plc
  • Intellipharmaceutics International, Inc.
  • Takeda Pharmaceutical Company Limited
  • Lundbeck A/S
  • Otsuka Holdings Co. Ltd.
  • Apotex, Inc.
  • Shionogi & Co. Ltd.
  • Zhejiang Hua Hai Pharmaceutical Co., Ltd
  • Chengdu Kanghong Pharmaceutical Group Co. Ltd.
  •  “*” marked represents similar segmentation in other categories in the respective section.
Table of Contents

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Key Highlights
  • PEST Analysis
  • PORTER's Five Forces Analysis
  • Pipeline Analysis

4. Global Depression Therapeutics Market, By Drug Type, 2017-2025, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2016 and 2025 (%)
    • Y-o-Y Growth Analysis, 2017-2025
    • Segment Trends
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2025, (US$ Mn)
  • Selective Norepinephrine Reuptake Inhibitors (SNRIs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2025, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2025, (US$ Mn)

5. Global Depression Therapeutics Market, By Distribution Channel, 2017-2025, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2016 and 2025 (%)
    • Y-o-Y Growth Analysis, 2017-2025
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2025, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2025, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2025, (US$ Mn)

6. Global Depression Therapeutics Market, By Regions, 2017-2025, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2016 and 2025 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2025
  • North America
    • Market Size and Forecast, By Drug Type, 2017-2025, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017-2025, (US$ Mn)
    • Market Size and Forecast, By Country, 2017-2025, (US$ Mn)
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Market Size and Forecast, By Drug Type, 2017-2025, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017-2025, (US$ Mn)
    • Market Size and Forecast, By Country, 2017-2025, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2017-2025, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017-2025, (US$ Mn)
    • Market Size and Forecast, By Country, 2017-2025, (US$ Mn)
    • China
    • India
    • Japan
    • Southeast Asia
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Market Size and Forecast, By Drug Type, 2017-2025, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017-2025, (US$ Mn)
    • Market Size and Forecast, By Country, 2017-2025, (US$ Mn)
    • Brazil
    • Argentina
    • Colombia
    • Rest of South America
  • Middle East & Africa
    • Market Size and Forecast, By Drug Type, 2017-2025, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017-2025 (US$ Mn)
    • Market Size and Forecast, By Country, 2017-2025 (US$ Mn)
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of Middle East & Africa

7. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Eily, Lilly, and Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AstraZeneca, Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Allergan Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Intellipharmaceutics International, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • H.Lundbeck A/S
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Otsuka Holdings Co. Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Apotex, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Shionogi & Co. Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Zhejiang Hua Hai Pharmaceutical Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Chengdu Kanghong Pharmaceutical Group Co. Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top